Cargando…
How I manage frontline transplant-ineligible multiple myeloma
The Multiple Myeloma (MM) is a plasma cells hematological malignancy with a median age of 69 years at diagnosis. The autologous stem cell transplantation is the standard of care for this disease but less than half of newly diagnosed patients are assessed for this treatment due to comorbidities or co...
Autores principales: | Derudas, Daniele, Capraro, Francesca, Martinelli, Giovanni, Cerchione, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PAGEPress Publications, Pavia, Italy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7520858/ https://www.ncbi.nlm.nih.gov/pubmed/33042505 http://dx.doi.org/10.4081/hr.2020.8956 |
Ejemplares similares
-
How I manage frontline transplant-eligible multiple myeloma in Italy
por: Montefusco, Vittorio, et al.
Publicado: (2020) -
How we manage smoldering multiple myeloma
por: Romano, Alessandra, et al.
Publicado: (2020) -
How I treat relapsed and/or refractory multiple myeloma
por: Lee, Hans C., et al.
Publicado: (2020) -
The Safety Profile of Concurrent Therapy for Multiple Myeloma in the Modern Era
por: Resende Salgado, Lucas, et al.
Publicado: (2018) -
MM-219: Outcome of COVID-19 Among Patients with Multiple Myeloma at the Armenian Hematology Center
por: Sahakyan, Lusine, et al.
Publicado: (2021)